Journal of **proteome** • research

Gentle Introduction to the Statistical Foundations of False Discovery Rate in Quantitative Proteomics

Thomas Burger*

BIG-BGE (Université Grenoble-Alpes, CNRS, CEA, INSERM), Grenoble 38000, France

ABSTRACT: The vocabulary of theoretical statistics can be difficult to embrace from the viewpoint of computational proteomics research, even though the notions it conveys are essential to publication guidelines. For example, "adjusted *p*-values", "*q*values", and "false discovery rates" are essentially similar concepts, whereas "false discovery rate" and "false discovery proportion" must not be confused, even though "rate" and "proportion" are related in everyday language. In the interdisciplinary context of proteomics, such subtleties may cause misunderstandings. This article aims to provide an easy-to-understand explanation of these four notions (and a few other related ones). Their statistical foundations are dealt with from a perspective that largely relies on intuition, addressing mainly protein quantification but also, to some extent, peptide identification. In addition, a clear distinction is made between concepts that define an individual property (i.e., related to a peptide or a protein) and those that define a set property (i.e., related to a list of peptides or proteins).



KEYWORDS: discovery proteomics, statistical analysis, FDR, quality control

1. INTRODUCTION

For a number of years, the proteomics community has been concerned with quality control (QC - see list of abbreviations, Table 1) methods that allow it to provide the most reliable

Table 1. List of Abbreviations Used in This Article

acronyms	meaning
QC	quality control
FDP	false discovery proportion
FDR	false discovery rate
PSM	peptide-spectrum match
PEP	posterior error probability

biological conclusions possible on the results it produces. In discovery proteomics, where large-scale approaches are now standard, the vast mass of data that is produced daily is difficult to reconcile with an expert-driven, refined, manual analysis. In this context, the role of QC has spread along the entire chain of interdisciplinary expertise, making statistics necessary in places where it was originally not expected. Recently, three publications related to false discovery rate (FDR) illustrated that a better understanding of statistical QC would be beneficial to the proteomics community:

• Serang et al.¹ explained that the vigorous debates around QC and data analysis when producing the first drafts of the human proteomes^{2,3} probably originated from confusion between at least two FDR-related notions.

• We argued⁴ that one of the methods most commonly used to compute FDRs in Perseus⁵ may rely on a distortion of *p*values that has already been described in the microarray literature;⁶ we also explain why these possibly incorrect *p*-values may nevertheless be compatible with biologically relevant results, in contradiction with what is generally expected of QC tools.

• The Human Proteome Project consortium⁷ proposed stringent guidelines to ensure that, in all publications linked to the project, thorough descriptions of how FDRs were calculated are presented alongside protein lists. Moreover, some additional validation criteria are required for any claim made about a specific protein.

These publications advocate for a better understanding and more discussions of FDR and related statistical notions. However, statistical vocabulary can be obscure and may cause confusion, which severely hinders these discussions. In fact, statistics is so deeply rooted in mathematics that it remains disconnected from most of its fields of application, ranging from proteomics to social sciences, where similar discussions are regularly published.^{8,9}

This tutorial is intended for use by computational engineers who work somewhere in the middle of the chain of expertise required for proteomics research and who represent an increasing proportion of this chain. The aim is to provide them with an easy-to-understand overview of the following notions: *p*-value, *q*-value, adjusted *p*-value, FDR, local-FDR, and false discovery proportion (FDP). Proteomics counterparts to some of these notions were introduced a long time ago, when it first became necessary to estimate the number of peptide spectra that were incorrectly identified. However, their connections to the theoretical foundations of statistics were (and remain) not trivial. More recently, these statistical notions also explicitly showed up in the quantification setting when attempting to determine which proteins are significantly

Published: October 25, 2017

differentially abundant between at least two biological conditions. Because the objective of this article is to relate these notions to the proteomics context, while also helping computational proteomics experts to connect to mainstream data analysis methods, the structure of the article has been reversed with regards to history: First, the quantification setting where the statistical notions are straightforwardly involved is presented. Afterward, we go back to the well-described peptide identification setting to unravel its statistical foundations.

2. THE *p*-VALUE: AN ANSWER TO A QUESTION THAT WAS NEVER ASKED

Let us consider a relative quantification proteomics experiment where the abundances of thousands of proteins are compared between several replicates split between two biological conditions (e.g., mutant vs wild type). We will call (see Figure 1):



Figure 1. Venn diagram illustrating the different notions presented in Section 2.

• Putative discovery: any protein quantified in the experiment

• *True discovery*: a protein that is differentially abundant between the biological conditions (generally, these proteins are sought for their potential biological interest)

• *False discovery*: a protein that is not differentially abundant between the biological conditions (generally, these proteins lack biological interest in the context of this experiment)

• Selected discovery: a protein that has passed some userdefined statistical threshold (generally this protein is expected to be biologically relevant; however, no one knows whether it is).

Alternatively, true/false-negative/positive taxonomy can be used. However, as already discussed, $^{10-12}$ *false-positive rate* and *false discovery rate* are different concepts that should not be confused. Because the former is not discussed in this article, it was decided to use the vocabulary creating least confusion.

Logically, any experimental practitioner would expect a statistical procedure to inform on whether each putative discovery can be classed as true or false. In this idealized case, the set of true discoveries and selected discoveries would concur. Unfortunately, because no procedure exists to produce such a binary classification in a completely reliable way, practitioners of many disciplines learned long ago to accept a probabilistic result and to select a set of discoveries based on a manually defined threshold on the range of probability values. When using this approach, the question naturally arises, "What is the probability that a putative discovery is false?" As an answer to this question, statistical procedures would be expected to provide a small probability value to indicate a true discovery and a high one to indicate a false discovery. In practice, statisticians compute the significance of a given protein's differential abundance using a *statistical test*, which returns a so-called *p-value* that behaves exactly as mentioned: small for differentially abundant proteins, large for the others. Because of this concordance, the *p*-value of one's favorite statistical test could be understood to correspond to the probability that a quantified protein is not differentially abundant. Unfortunately, this is not the case.¹³

To understand why, we will use a simpler interpretation of probabilities. Although the *p*-value is an "individual property", related to a given protein, it is more intuitive to understand a probability value (in general, not necessarily a *p*-value) as a "set property", and, more precisely, as a proportion. In general terms, the probability that a random experiment will succeed can be expressed as the proportion of success among trials. This intuitive interpretation can be extended to our case. Concretely, "the probability that a putative discovery is false" can be viewed as the proportion of false discoveries among the set of similar putative discoveries

$$\frac{\#\{\text{false discoveries}\}}{\#\{\text{putative discoveries}\}} := \pi_0 \tag{1}$$

and which will be referred to as π_0 from now on. This proportion should be low if the putative discoveries considered are true discoveries and high otherwise. Now, let us compare this proportion to the one reflected by *p-values*, which reads

$$\frac{\#\{\{\text{false discoveries}\} \cap \{\text{selected discoveries}\}\}}{\#\{\text{false discoveries}\}}$$
(2)

Obviously, eqs 1 and 2 differ, and it becomes clear that *p*-values are not meant to quantify the "probability that a putative discovery is false". In fact, a *p*-value is an answer to another question entirely, "What is the probability that a given false discovery is included in the set of selected discoveries?"

In practical terms, this question is more complicated to understand, and its answer is less interesting. However, this is the answer provided by statistical tests because it is much simpler to compute. This can be explained as follows: Most of the time, the amount of data available is insufficient to precisely estimate π_0 for any possible type of putative discovery. As we will see later, it is often possible to provide rough estimates of this ratio, at least when one considers all of the putative discoveries together. However, this π_0 "averaged on the entire dataset" is not accurate enough to allow selection, or not, of each individual putative discovery. This is why, instead of providing a relatively unreliable answer based on a rough estimate, statisticians propose to use a procedure (namely, the statistical test) that provides an answer (the p-value) to a different question. The question answered is more difficult to relate to the original problem, but its answer is more robust.

3. STATISTICAL TESTS: WHY HAVING "ENOUGH DATA" IS NECESSARY

Statistical tests are based on the idea that false discoveries are extremely frequent, unlike true discoveries, which are scarce. In other words, a true discovery amounts to a notable fact, whereas a false discovery is a standard observation. Thus if "enough data" are available (i.e., a large enough number of proteins to test), then statisticians can define a "standard" based on false discoveries (which, in statistical jargon, is termed the *null hypothesis*) and characterize its statistical behavior (by means of a distribution termed the *null distribution*). However,

it is unlikely that the number of true discoveries will be sufficient to precisely characterize their statistical behavior (by means of another distribution).

Thus the duty of statisticians is to determine whether a putative discovery is true or false by relying only on the null distribution. To achieve this, the hypothesis testing framework classically proposes to quantify the similarity between the putative discovery and the null distribution by means of a metric called test statistic. Concretely, for any given quantified protein, the expected "standard behavior" is that of nondifferential abundance (or at least, that the difference in abundance can largely be explained by random fluctuations). According to the theory, the similarity between a protein (depicted by a vector of abundances grouped in two sets of replicates) and the null distribution should be measured using any statistic from the Student family. Because Student's statistics are difficult to interpret, they are replaced by *p*-values, with the following interpretation: For a given protein X, a pvalue of 1% indicates that only 1% of the false discoveries will be less similar to the "standard behavior of false discovery" than protein X, which can be directly related to eq 2.

The development of the traditional hypothesis testing framework is previous to the advent of big data. As explained in the next section, it is now possible to leverage the big data context to better characterize the mixture of true and false discoveries.

4. THE FDP: WHY HAVING "BIG DATA" IS IMPORTANT

Let us now assume that more data are available than in Section 3 (even if the corresponding number of proteins is not yet precisely defined). Our intuition tells us that with the number of observed true discoveries being mechanically greater, it should become possible to build some meaningful statistics on the true discoveries. Although fully specifying their distribution is most of the time not possible (as one does not know which putative discoveries are true or false), this intuition is nonetheless essentially correct: Notably, we will see that it is at least possible to provide a rough estimate for π_0 (eq 1). Then, on its basis, it becomes possible to estimate another quantity

$$\frac{\#\{\{\text{false discoveries}\} \cap \{\text{selected discoveries}\}\}}{\#\{\text{selected discoveries}\}} := \text{FDP}$$
(3)

Although this equation still does not answer the original question (for each protein, what is the probability that it is a false discovery?), it nevertheless gives an interesting hint, as it answers a related question: Among all the selected proteins, how many are false discoveries? In fact, this approach is simply a shift from a question that relates to an individual protein (the probability that it is a false discovery) to a question that relates to the entire set of proteins (the proportion of false discoveries it contains). This shift from "individual property" to "set property" makes it possible to answer the question, and the resulting quantity is referred to as the *false discovery proportion* (or *FDP*). At this point, it should be noted that the FDP is often called the FDR in proteomics. However, as we will see below, this is an oversimplification because an FDR does not exactly coincide with the FDP.

First, we have to grasp why it is possible to estimate this FDP. In fact, even if characterizing the behavior of the putative discoveries themselves is a problem (so far, a manageable one for false discoveries and an insoluble one for true discoveries), statisticians have a very precise idea of how their resulting p-values behave:

• The *p*-values for true discoveries are relatively simply characterized: They are small; instead of being spread across the [0,1] interval, they are concentrated in a small region close to 0, as depicted on the histogram shown in Figure 2a, illustrating a simulated data set where all of the proteins are truly differentially abundant.



Figure 2. (a) Histogram representing p-values for a data set in which 100% of proteins are differentially abundant. (b) Histogram representing p-values for a data set in which the proteins are not differentially abundant.

• The *p*-values for false discoveries, in contrast, display counterintuitive behavior: One would expect them to distribute within the upper range of the [0,1] interval. If this were the case, then it should be possible to find a threshold discriminating between low *p*-values (true discoveries) and high *p*-values (false discoveries). However, this frequent idea fails to consider how *p*-values are constructed: A *p*-value of X% indicates that among false discoveries (and only them), exactly X% of the other *p*-values will be lower than X%, whereas the others will be greater. As a result, the *p*-value for false discoveries must uniformly distribute across the [0,1] interval. Figure 2b illustrates a simulated data set where none of the proteins are differentially abundant.

Consequently, if a quantitative data set contains a proportion π_0 of false discoveries and $1 - \pi_0$ of true discoveries, then the histogram should theoretically look like the one shown in Figure 3a, which represents a combination of those in Figure 2. In practice, histograms for real data are not this "clean" (see Figure 4). However, to understand the logic underlying estimation of the FDP, it is best to work in the "cleaner" theoretical case. If we zoom in on the left-hand side of this histogram (see Figure 3b), then two observations can be made:

• First, it would be good to be able to tune the selection threshold to select all of the true discoveries and a minimum number of false discoveries, as illustrated by the vertical dashed line in Figure 3b.

• Second, if the data set is "big enough", then the histogram tends to be smooth. In this case, it becomes possible to determine a first rough estimate of the FDP by computing the ratio depicted by the colored boxes in Figure 3b.

To compute this ratio, we must introduce some additional notation. Let:

• α be the user-tuned *p*-value threshold (the vertical dashed line in Figure 3b)



Figure 3. (a) *p*-value histogram for a data set composed of $100\pi_0$ % of false discoveries and $100(1 - \pi_0)$ % true discoveries (here $\pi_0 = 0.97$). (b) Zoom on the left-hand side of the histogram, where α corresponds to the selection threshold.



Figure 4. Histogram of the *p*-values associated with the differential abundances of the proteins from the Exp1-R25-prot data set:¹⁴ In red, the yeast proteins from the background, in green, the human UPS1 proteins.

• m be the total number of putative discoveries in the data set

• *k* be the number of selected discoveries

On this basis, a first estimator of the FDP can be simply derived as the proportion, α , of the total number of false discoveries, $m \times \pi_0$ (i.e., the numerator on the colored-box formula from Figure 3b), divided by the total number of selected discoveries, k (i.e., the denominator)

$$FDP \approx \frac{\alpha \times m \times \pi_0}{k} := \widehat{FDP}$$
(4)

Of course, this estimate is rather crude. This is why one uses the "hat" notation: It is helpful to recall that it is not strictly speaking equal to the FDP. However, it illustrates that it is possible to leverage the large amount of putative discoveries to produce a smoother histogram, from which additional information can be extracted.

As already mentioned, our reasoning was based on a theoretical histogram. In practice, the data seldom distribute exactly as expected. For instance, Figure 4 shows the *p*-value

histogram for the Exp1_R25_prot data set¹⁴ provided in R package CP4P. This data set is derived from a differential analysis of proteins in two groups of three replicates. The protein samples contain an equal background of yeast proteins, into which UPS1 human proteins have been spiked.¹⁵ In the second condition, the concentration of UPS1 is 2.5 times larger than in the first, so that in the end all of the UPS1 human proteins (and only them) should be differentially abundant. After individually testing each protein (either human or yeast), a list of *p*-values is obtained for which the histogram is shown in Figure 4.

Comparison of the histograms in Figures 3 and 4 shows that the silhouettes do not match.¹⁶ The difference in behavior between the true and false discoveries is blurred, making it impossible to precisely define α and π_0 and thus to accurately estimate the FDP with eq 4. This is why it has been necessary to rely on statistical theory to develop more robust estimators for the FDP, as discussed in the next section.

5. WHAT ARE FDRS?

Essentially, an FDR is an estimate of the FDP that is endowed with some important statistical properties (see Efron's book¹⁷ for a survey of the subject). Mainly, an FDR must be

• *Conservative*: That is, it should not underestimate the real FDP, or, at least, it may do so but only with a controlled probability. This is essential to ensure that the number of false discoveries selected does not exceed the number estimated (and accepted). In other words, conservativeness is essential to the QC of the biological conclusions.

• Asymptotically convergent: That is, in the long run, the average of a large number of FDR computed on data sets with the same statistical distributions should tend toward an upperbound of the real FDP.

Statisticians have worked extensively on these properties but have unfortunately failed to reach a consensus on their precise implementation. For instance, even their mathematical definitions differ slightly depending on whether we use Benjamini and Hochberg's framework^{19–22} (BH) or that developed by Storey and Tibshirani^{23–27} (ST). However, from the practical viewpoint of proteomics data analysis, these technical details have little or no influence; in fact, the BH and ST families are similar on many points, and these common elements are those on which it is important to focus.

First, both families are more or less related to the naive estimator of the FDP discussed above (see eq 4). Consequently, FDRs from both families need to estimate π_0 .

Second, both families have the same type of "relatively weak" sensitivity with respect to the volatility of the estimate of π_0 . Conveniently, it is not essential to precisely determine π_0 (although it would be a bonus); what really matters is to avoid its underestimation. This is why, in the original work of Benjamini and Hochberg, they used $\pi_0 = 1$. This is also why in the Introduction we spoke about using a rough estimate for π_0 . A precise estimation would be necessary to reliably define the probability that a putative discovery is false, but a hand-waving overestimator is sufficient to produce a good FDR (regardless of whether it is a BH or an ST one). Finally, this explains why numerous statistical works¹⁴ have been devoted to defining different π_0 estimates that can be inserted into the different BH and ST frameworks.

Third, both families can be cast into the same algorithmic procedure, summarized as follows:

1. Sort putative discoveries by increasing *p*-values

$$p_{\min} = p_{(1)} \le p_{(2)} \le \dots \le p_{(m-1)} \le p_{(m)} = p_{\max}$$
 (5)

2. Walk through the list of *p*-values from $p_{(1)}$ to $p_{(m)}$, and for each $p_{(k)}$, $k \in [1,m]$

2.1. Assume that in eq 4, one tunes $\alpha = p_{(k)}$ (i.e., α is tuned to select exactly the first k discoveries) and compute the resulting naive estimate

$$\widehat{\text{FDP}}(k) = \frac{p_{(k)} \times m \times \pi_0}{k} \tag{6}$$

2.2. Store $\widehat{FDP}(k)$ in the *k*th cell of an intermediate table 3. Walk through this intermediate table, from 1 to *m*

3.1. Compute the FDR associated with the set of the k best discoveries, that is, the set {protein₍₁₎, ..., protein_(k)}, by applying the following computation

$$FDR(\{\text{protein}_{(1)'}, \dots, \text{ protein}_{(k)}\}) = \min_{i \ge k} (\widehat{FDP}(i))$$
(7)

3.2. Store the corresponding FDR in the kth cell of the result table.

4. Walk through the result table from 1 to *m* and stop just before meeting an FDR value that is greater than acceptable (say β %). Let *N* be the index of this value. The set {protein₍₁₎, ..., protein_(N)} therefore has an FDR of β %, which means one can roughly assume its FDP is slightly smaller than β %.

As indicated at the very beginning of this tutorial, q-values, adjusted p-values, and FDR are rather similar concepts.²⁸ We will now explain why. If one incorporates eq 6 into eq 7, then one obtains

$$FDR(\{\text{protein}_{(1)}, \dots, \text{protein}_{(k)}\}) = \min_{i \ge k} \left(\frac{m \times \pi_0}{i} \times p_{(i)}\right)$$
(8)

which underlines FDRs at various decision thresholds can be derived from applying a transform to the list of *p*-values, leading to the terms *adjusted p-value* (BH literature) or *q-value* (ST one).

The problem with this type of naming convention is that it sometimes leads nonstatisticians to severely misunderstand the significance of terms. The most common misunderstanding here is that q-/adjusted p-values are merely corrections of pvalues, closely connected to them rather than to the concept of FDR. It is of the utmost importance to remember that a *p*-value is an individual property, whereas an FDR, an adjusted *p*-value, or a q-value are set properties. Thus a p-value relates only to the individual putative discovery with which it is associated and nothing else; if the rows in a table of proteins associated with pvalues are shuffled, filtered out, or merged with another table, then the *p*-values remain meaningful. In contrast, any FDR, adjusted *p*-value, or *q*-value relates to a set. Even if it looks like this value is associated with the kth putative discovery, it is in fact linked to the entire set of putative discoveries with smaller *p*-values. Thus if the table of proteins is ordered by increasing p-values, then FDR, adjusted p-value, or q-value is meaningful (it relates to the set of lines above), but if the lines of the table are shuffled, then there is no visually obvious way to relate the FDR, adjusted p-value, or q-value to the set to which it corresponds. Similarly, any modification of the data table (for instance, protein filtering on the basis of biological evidence, or merging with another data set) will make the FDR spurious.

6. LOCAL-FDR: WHY HAVING "EVEN BIGGER" DATA IS AN ADVANTAGE

Our line of reasoning so far was as follows: If sufficient knowledge on the behavior of the data has been garnered, then "standard behavior" can be defined (known to statisticians as the null hypothesis distribution), and thus each putative discovery can be tested individually. If a large number of putative discoveries are considered simultaneously, as in any high-throughput omics experiment, then the *p*-value distribution (or histogram) can be used to define a conservative estimate of the FDP, termed FDR. This FDR can be used as a QC measure, as an FDR of X% can be used to claim something like, "The proportion of falsely differentially abundant proteins in my protein list is likely to be lower than or equal to X%." Although useful, this FDR remains a set property that qualifies the entire protein list, whereas an individual QC metric for each protein would be of greater interest. As indicated in the Introduction, it is generally not possible to refine the QC metrics for individual proteins; however, with large data volumes, an "in-between" measure can be defined that only

fits a restricted subset of putative discoveries, which are to some extent similar.

To understand how, we must assume that for a given experiment our protein list appears to be ten times longer than usual. Thus the list can be clustered into 10 homogeneous groups sharing common features. Within each group, the number of proteins remains large enough to allow calculation of a specific FDR for each group individually, following the line of Section 5.

To define these homogeneous groups, a first solution is to rely on any available covariates. For instance, proteins can be grouped according to the number of peptides identifying them (the underlying rationale being that the more peptides identified, the more reliable the quantification). Alternatively, one can rely on the ratio of missing quantitative values or any other covariate related to the quality of each protein quantification. The FDR computed for a group of "higher quality" would be expected to be smaller than that for a group of "lower quality".

Another solution is to define the groups according to the test statistics itself. In this case, the proteins are sorted by increasing *p*-value, and for each possible value, only the subset of proteins belonging to a specific interval around is considered. Thus a "sliding subset" of proteins emerges rather than a hard clustering into groups. This approach produces a locally defined FDR for each point of the range of *p*-values, as illustrated in Figure 5, and is known as local-FDR.¹⁷ Finally, a



Figure 5. Local-FDR is used to estimate the FDP locally, in contrast with the classical FDR (see Figure 3b), which is a global estimate.

local-FDR is a QC measure that relates to such a small set that it is nearly an individual property. Although it sounds convenient, local-FDR is a double-edged sword. In the limit case where the histogram depicted in Figure 5 is perfectly smooth (which would require an infinite number of proteins), the local-FDR converges toward the probability that a selected discovery is false. This probability, which we have been looking for since the Introduction, finally becomes accessible, at least in theory. However, in practice, infinite data cannot exist; at best, one "only" has a huge volume of data, producing a "reasonably" smooth histogram that is compatible with computation of a fairly robust local-FDR. If the volume of data is not large enough, then the histogram profile will be too irregular and local estimates will be unstable. Thus a trade-off must be sought between the "locality" of the estimate (the more local the better) and its robustness (the more local, the less robust). Although proteomics researchers classically desire the most refined local QC metrics, it is the computational engineer's duty to advise the use of more global ones if they are the only ones to be trusted.

When comparing these two approaches, let us note that local-FDR uses a single null distribution for all of the sliding windows, whereas on the contrary, in the per-group computation of FDR, one commonly uses a specific null distribution for each.

7. UNVEILING THE STATISTICAL FOUNDATIONS OF FDR AT THE IDENTIFICATION STEP

So far, we have only relied on quantitative analysis because it naturally matches the statistical framework of hypothesis testing. However, from a historical perspective as well as from the viewpoint of data processing, FDR is primarily associated with identification QC. In this setting, the practical goal is to filter out incorrect *PSM* (peptide-spectrum matches), so as to retain only correct ones. Unfortunately, it is less intuitive to relate the identification QC problem to the hypothesis-testing framework. This state of affairs may lead to misinterpretation of results and, consequently, to spurious conclusions, as recently discussed.²

The purpose of this section is not to describe the identification workflow from a theoretical statistics viewpoint. Its objective is more humble. It is only to link the theoretical foundations of FDR to the practical setting of PSM validation. To do so, one needs to find in the PSM validation process different elements that can be considered as counterparts to the building blocks of FDR theory that have been described in Sections 4 and 5. Concretely, one needs to check that (1) true and false discoveries are properly defined; (2) a null distribution is available; (3) a test statistics can be used to derive *p*-values on which a mixture model equivalent to that of Figure 3 can be constructed; and (4) an estimate of the FDP such as eq 4 is available.

7.1. True and False Discoveries Definition

Because true discoveries are what we are interested in, they should be defined as correct PSMs. Consequently, false discoveries should be the incorrect PSMs and putative discovery can therefore be defined as any possible pair of the type {Peptide; Spectrum}, regardless of whether it is correct or incorrect. Thus the set of putative discoveries is more abstract than in the quantitative analysis, becoming a combinatorial set (i.e., made of a series of possible combinations).

7.2. Null Distribution

If a {Peptide; Spectrum} pair is randomly selected from among all possible pairs, then it is highly unlikely to have a correct PSM by chance. In other words, the "standard" is for PSM to be incorrect. However, it is harder to qualify a mismatch than a match, or to paraphrase Leo Tolstoy, "All correct PSMs are alike; each incorrect PSM mismatches in its own way." Clearly, this makes it more difficult to define a "standard" than in the quantification setting (where equal abundance distribution was



Figure 6. Schematic illustration of the conceptual link between identification scores and *p*-values: The arrows indicate how it is possible to shift between a *p*-value histogram and a mixture model representation, so that direct FDR computation on the basis of identification scores is theoretically supported.

sought). Fortunately, this difficult task is conducted by most database search engines, so that practitioners need not worry about it.

7.3. Test Statistics and *p*-Value Existence

Unraveling these notions is clearly the most difficult issue: In numerous cases, the test statistics and the *p*-values are computed within the identification engine, yet they are not provided. Rather, they are transformed into scores that form the only output accessible to the user. Then, the output score, noted S_i for the *i*th peptide-spectrum pair, is related to a *p*-value, p_i , by a formula such as the following

$$S_i = -10 \log_{10} p_i \tag{9}$$

As a result of this one-to-one correspondence between scores and p-values, to compute an FDR, it is possible to directly work with the histogram of output scores instead of that of p-values, as illustrated in Figure 6. Concretely, what really matters is to have a mixture model to rely on, and whether it depicts p-values or output scores seldom matters. In fact, the conceptual links between the mixture model and the computation of the FDR are so strong that it is sometimes possible to bypass the p-value computations and to empirically define the null distribution directly on scores (chapter 6 of ref 17). This explains why there also exist identification tools where p-value computation is even not performed as an intermediate step. Similarly, to discriminate between correct and incorrect PSMs, numerous postprocessing tools (e.g., PeptideProphet³⁰) directly rely on a mixture model of scores as the one illustrated on the lower right-hand panel of Figure 6. However, it is very important to keep in mind that there always exists a histogram of *p*-values that could be used in place of the mixture model and that this is the very reason why FDR computation is theoretically supported. If this histogram did not exist, then there would be no guarantee that conclusions drawn from the mixture model would be valid. For instance, database search engines exist with a scoring system that cannot be directly interpreted in terms of *p*-values (mainly because PSMs are not scored independently from one another). Some authors³¹ point out that such scoring systems may not be compliant with classical FDR computation procedures.

7.4. FDP Estimate

At first glance, this is where the main difference between identification and quantification lies, as the so-called targetdecoy approach³² is used instead eq 4 to estimate the size of the red rectangle shown in Figure 3b. However, from a theoretical viewpoint, the underlying rationale is really similar. The purpose of target-decoy methodology is to artificially create a large number of false discoveries that can be easily traced (because the peptide involved in each {Peptide; Spectrum} pair is a random sequence of amino acids that does not exist in the protein sequence database). As a result, once the practitioner has cut the PSM list at a given score threshold, then the PSMs

with a real peptide (termed "targets") can be distinguished from the others (termed "decoys") to compute the proportion of decoy PSMs. In this scenario, the strong assumption is made that mismatches (involving a real peptide) have the same distribution of scores as the decoy PSMs, so that among the PSMs above the threshold, the number of false discoveries can be derived from the number of decoys.³³ Although the approach is empirical, it can be demonstrated to fit in the classical FDR framework.^{10,33} However, as a side effect, the same weaknesses as with the classical FDR computation procedure affect target-decoy approaches: An overly biased estimate of π_0 may affect the results,³⁴ the size of the decoy database and the uniformity of sampling of the false discoveries are critical,¹⁰ the volatility of the FDP estimate may require a control of the confidence interval,³³ and so on.

8. FROM PEPTIDE-LEVEL LOCAL-FDR TO PROTEIN-LEVEL FDR

In Section 7, we uncovered the relationships between classical statistics-based FDP estimation and target-decoy approaches. We concluded with a few weaknesses of the target-decoy approaches, which are directly inherited from statistical theory. Now we present a more optimistic viewpoint, by leveraging this theoretical connection to define local-FDRs for peptide identification.

The first approach applies the same line of reasoning as depicted in Figure 5 (where the local-FDR is derived from the histogram of *p*-values) to the histogram of scores (e.g., lower right-hand part of Figure 6) to produce the computation illustrated in Figure 7. This procedure returns the so-called *posterior error probability* (or **PEP**), which is already a popular alternative to FDR.^{35–37}





Another approach is to cluster PSMs according to some additional covariate(s) and to provide a specific FDR for each cluster. Reiter et al.³⁸ propose to cluster the target and decoy PSMs based on the identities of the parent proteins to produce a target-decoy-based estimate of the FDP at the PSM level for each protein. Because the putative discoveries are split between an enormous number of clusters (as many as proteins), it is rather difficult to gather enough data within each cluster to achieve reliable FDP estimates. Because the size of the data set is essential to its successful application, the article title indicates

that the methodology is applicable with "very large proteomics data sets". However, its main feature is not that it proposes a PSM-level FDR for each protein but that it transforms the PSM-level FDRs into a protein-level FDR. This is achieved by modeling each protein by the random draw of a series of colored balls from an urn (say the black balls represent the decoy peptides and the white ones the target peptides). The outcomes of this type of random experiment are known to distribute according to hypergeometric law (with different parameters for correct and incorrect proteins), making it possible to define the "standard behavior" of proteins with respect to the distribution of target and decoy peptides. Consequently, a null hypothesis distribution is produced, making it possible to define protein-level *p*-values (or scores) and thus an FDR.

Much effort has been devoted in recent years to defining a protein-level FDR. However, it is a complex issue. As recently discussed,¹² the very definition of truly and falsely identified protein absent from the sample? Or is it the result of an inference from incorrectly validated PSMs (even though a protein can be correctly identified on the basis of incorrect peptide-level evidence)? While practitioners expect the first case, the solutions currently available tend to be based on the second.

Another difficulty relates to the following simple observation: To compute an FDR at the protein level, putative discoveries must be defined as putative protein identifications, endowed with a score of known distribution for incorrect identifications (to define the null hypothesis). Unfortunately, analysis is conducted at peptide level, and it is therefore necessary to aggregate the peptide-level scores into protein scores while precisely controlling how the aggregation process influences the distribution of scores (for both true and false identifications). In general, this aggregation remains a very difficult statistical subject, for which only a few results are available to date. In the specific case where the data set is very large, the hypergeometric model, as proposed by Reiter et al.,³⁸ can be effectively applied. For smaller data sets, no strategy dominates the state-of-the-art (section 7 of ref 11). Because no strategy is perfect, an additional source of errors may be introduced during aggregation. Then, one runs the risk of increasing the difference between the real FDP and the computed FDR when shifting from peptide level to protein level.

Of course, the expectations of wet-lab researchers for protein-level QC are legitimate because they are easier to interpret and relate to the biological problem. However, in the meantime, computational experts must determine whether this increment of biological interpretability is worth authorizing hidden and unwanted distortion of the QC metrics. To the best of the author's knowledge, no survey has benchmarked the various protein-level FDRs so far from this angle. Therefore, computational experts currently have no material with which they could find a trade-off between the gain in interpretability and the possible loss of accuracy this distortion might produce.

9. PRACTICAL RECOMMENDATIONS AND DISCUSSION

In this section, the theoretical background reviewed so far is used to derive some guidelines. However, one should recall that statistical science has developed like many other sciences: First are the foundations, consisting of basic, commonly accepted, and rarely discussed knowledge that can be presented in tutorials. From these foundations, different protocols have emerged based on each individual's experience: These protocols are somewhat subjective, as two different ones may be equally correct. As a result, unlike the rest of the article, the elements given here remain debatable and amendable. This being noted, a few very practical questions will now be addressed.

1. Concretely, what does "enough", "big", or "even bigger" data mean? For instance, at what point is it safe to consider the volume of data to be large enough to compute local-FDR?

2. Throughout the text, "user-defined thresholds" were referred to with regards to scores, *p*-values, or FDRs, but how should these thresholds be tuned in practice?

3. When processing real-life data sets, researchers focus not only on the scores or the *p*-values but also on an important number of covariates that are known to be relevant. How can these be accounted for in the statistical framework presented so far?

With regards to the first point, it is at least possible to define orders of magnitude. For example, in Section 3, "enough data" referred to the fact that it was possible to garner sufficient observations to define the null distribution. However, in proteomics, either for identification or quantification, the statistical tests that should be used (and the corresponding null distributions) are well known: the beta-binomial test for spectral count data,³⁹ Student family tests for eXtracted Ion Chromatogram data, the tests embedded by search engines for identifications, and so on. As a result, this issue is practically resolved. Next, we know that "big data" are necessary to compute an FDR, so that the question arises, :When does an FDR become meaningful?" Intuitively, it is best to avoid talking about a percentage of false discoveries if there are fewer than one-hundred selected discoveries (what would be the meaning of 1% FDR on a list of 35 proteins?). However, even 100 discoveries may be borderline. In fact, to represent the histogram of the data, as illustrated in Figure 4, it appears that smoothness requires more than 100 observations, so that a few hundred (e.g., from 500 to 1000) make more sense. Finally, "even bigger data" is required to define local-FDRs. We considered two cases: In the first one, the data set is binned into N groups for which N separate FDRs are computed, so that one naturally needs to have N times more data to achieve reliable estimates. Otherwise, it may be wiser to forget local-FDR and to stick to more global QC measures. In the other cases where a "sliding set of discoveries" was considered, such as with Efron's local-FDR or with PEP, the issue relates more to the regularity of the distribution (see Figure 4) than to the volume of data. Therefore, no simple general rule holds (ref 35 and chapters 5 and 7 in ref 17).

Before addressing the two remaining questions (user-defined thresholds and covariates), let us go back to the reason why FDR is necessary in proteomics. From what we have discussed so far, in statistics, *FDR Control* mainly relies on an <u>estimation procedure</u>: Given a list of *m* discoveries, we first attempt to estimate an upper-bound of the FDP in the *k* first elements of the list, $\forall k \leq m$. Second, on the basis of this estimate, the value for *k* can be chosen so as to fit with a user-expected FDR value. Basically, once the estimate has been calculated, the FDR control simply amounts to adjusting some threshold to cut the list to the right length.

Conversely, from a proteomics viewpoint, *FDR Control* is mainly based on <u>filtering procedures</u>: The issue is largely to prevent the spread of false discoveries through the application of stringent procedures derived from some proteomics expertise. To do so, the practitioner defines several knowledge-based filters at PSM, peptide, or protein level, for instance,¹² mass accuracy, peptide retention times, peptide length, compliance with digestion rules, a priori amino acid sequences, protein length, or a minimal number of matching peptides (e.g., the two-peptide rule). Similarly, at the quantification step, proteins with too many missing values can be filtered out,⁴⁰ as can proteins for which the fold-change is too low.⁵ These are common good practices that are experimentally proven to reduce the number of false discoveries. In real terms, they amount to sorting the discoveries according to additional covariates that the practitioner can interpret.

False discovery estimation (the statistician's viewpoint) and false discovery filtering (the practitioner's viewpoint) are two different approaches that are both important for QC. First, both of them have drawbacks. As previously explained, false discovery estimation is based on asymptotic theory: Even if the FDP will be well-controlled in the long run average, the FDR cannot be used as a precise and rigorous equivalent of the FDP in any single given proteomics experiment. On the contrary, false discovery filtering is no better: Even if the filters are plainly sensible, they provide no estimation of the FDP. Second, both approaches are interesting: Filtering relates to the practitioner's capacity to keep a critical eye on his/her own proteomics experiment to publish the most reliable material, whereas false discovery estimation provides statistical guidelines that mainly guarantee that results from different articles can be cross-compared and that different experiments from different researchers involve the application of a similar trade-off between the risk of publishing false discoveries and the benefit of publishing the longest possible list of true discoveries.

Finally, the two viewpoints are complementary, and it makes sense to start by filtering out false discoveries by multiplying stringent procedures and to subsequently estimate their proportion on the final filtered list. With this in mind, we will now address the issue of how to tune the *p*-value/score/ FDR thresholds. These thresholds are of little interest in the practitioner's context of false discovery filtering but are of prime importance to estimate the number of false discoveries. Thus depending on who will receive the results of the proteomics analysis, these thresholds may or may not be important. For example:

• To publish, it is mandatory to apply a classical threshold (say 1% FDR if the journal does not stipulate a specific value) so as to allow cross-comparisons with other published data, as mentioned above.

• If the proteomics analyses are part of a preliminary study, where a good trade-off between false selected discoveries (in a classical QC perspective) and unselected true discoveries (so as to maximize proteome coverage) is sought, then it makes sense to rely on the Receiver Operating Characteristic (ROC) curve⁴¹ to define the optimal FDR level.

• On the contrary, if the results are sent to a partner lab who only has the funds to manually validate, let us say, 15 proteins, regardless of the number of significantly differential ones, then it is not necessary to compute an FDR at a specific level: The ID of the 15 proteins with the lowest *p*-value should be transmitted to the lab (keeping in mind that transforming *p*-values into *q*- or adjusted *p*-values does not modify their ranking). Then, computing the PEP for these 15 proteins may be an additional QC metric, the advantage of which will mainly depend on whether the collaborators can interpret it.

Finally, the definition of these statistical thresholds is very context-dependent, and they should not be given more than appropriate importance.

Let us now turn to the question of covariates. As it should have appeared to the reader, the theoretical foundations of FDR are already complex without trying to account for any discipline-specific covariates. As a result, computational experts working in proteomics may have a hard time defining asymptotically convergent and conservative estimates that natively incorporate these covariates. However, these covariates are useful for false discovery filtering as proteomics expertise relies on them, and there is no reason to omit them. This is why, during the filtering step, all of the covariates can be used to define stringent filters, either by hand or by relying on machine-learning algorithms (e.g., Percolator⁴²). This approach should produce a more reliable list of discoveries according to the data owner, on which, as a final QC, an FDR can be computed (based only on the *p*-values or their related scores, regardless of the other covariates).

10. CONCLUSIONS

Over the past few years, the throughput of LC-MS/MS experiments has dramatically increased so that proteomics has now definitively entered the realm of big data. As a result, computational experts are playing an increasingly significant role in proteomics laboratories, where they make the link between mass spectrometry expertise and biological expertise. In this context, this article revisited the statistical foundations of several concepts (see Table 2 for a summary), so as to provide

Table 2. Summary of the Concepts Reviewed in This Article	Table 2.	Summar	y of the	Concepts	Reviewed	in	This Article
---	----------	--------	----------	----------	----------	----	--------------

concept	definition	applies to
concept	deminuon	applies to
<i>p</i> -value	quantifies the extent to which a discovery has a standard be- havior, nor not	individual
PSM score	replaces the <i>p</i> -value in the peptide identification setting (but is directly derived from it)	individual
FDP	the real, yet unknown, ratio of false discoveries among selected discoveries	set
FDR/q-value/adjusted p-value	the statistical quantity that is used to conservatively estimate the FDP	set
local-FDR/PEP	an FDR computed on a homo- geneous subset of discoveries	in-between

computational experts with additional skills when implementing data processing routines or exploiting the data produced on a daily basis in their laboratories. This evolution of proteomics toward data sciences will continue and in the near future will generate unprecedented opportunities to investigate proteomes. Thanks to a better understanding of all of these FDR-related notions, more refined QC of proteomics data will be possible, either through new types of experiments leading to even larger data sets or through meta-analyses of the extensive data volumes already available in public databases.

AUTHOR INFORMATION

Corresponding Author

*E-mail: thomas.burger@cea.fr. ORCID [®]

Thomas Burger: 0000-0003-3539-3564

Author Contributions

T.B. is the only contributor to this article.

Notes

The author declares no competing financial interest.

ACKNOWLEDGMENTS

The author acknowledges financial support from "Agence Nationale de la Recherche", "Infrastructures Nationales en Biologie et Santé", and "Investissements d'Avenir" under grant numbers ANR-10-INBS-08 (*ProFI* project), ANR-15-IDEX-02 (*Life (is made of choice)* Project) and ANR-10-LABEX-04 (GRAL labex). The author also thanks Quentin Giai Gianetto for fruitful discussions.

REFERENCES

(1) Serang, O.; Käll, L. Solution to statistical challenges in proteomics is more statistics, not less. *J. Proteome Res.* **2015**, *14* (10), 4099–4103. (2) Kim, M. S.; Pinto, S. M.; Getnet, D.; Nirujogi, R. S.; Manda, S. S.; Chaerkady, R.; Madugundu, A. K.; Kelkar, D. S.; Isserlin, R.; Jain, S.; et al. A draft map of the human proteome. *Nature* **2014**, *509* (7502), 575–581.

(3) Wilhelm, M.; Schlegl, J.; Hahne, H.; Gholami, A. M.; Lieberenz, M.; Savitski, M. M.; Ziegler, E.; Butzmann, L.; Gessulat, S.; Marx, H.; et al. Mass-spectrometry-based draft of the human proteome. *Nature* **2014**, *509* (7502), *582–587*.

(4) Giai Gianetto, Q.; Couté, Y.; Bruley, C.; Burger, T. Uses and misuses of the fudge factor in quantitative discovery proteomics. *Proteomics* **2016**, *16*, 1955–1960.

(5) Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M. Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote) omics data. *Nat. Methods* **2016**, *13* (9), 731–740.

(6) Larsson, O.; Wahlestedt, C.; Timmons, J. A. Considerations when using the significance analysis of microarrays (SAM) algorithm. *BMC Bioinf.* **2005**, *6* (1), 129.

(7) Deutsch, E. W.; Overall, C. M.; Van Eyk, J. E.; Baker, M. S.; Paik, Y. K.; Weintraub, S. T.; Lane, L.; Martens, L.; Vandenbrouck, Y.; Kusebauch, U.; Hancock, W. S.; Hermjakob, H.; Aebersold, R.; Moritz, R. L.; Omenn, G. S. Human proteome project mass spectrometry data interpretation guidelines 2.1. *J. Proteome Res.* **2016**, *15*, 3961–3970.

(8) Gigerenzer, G. Mindless statistics. *Journal of Socio-Economics* 2004, 33 (5), 587–606.

(9) Trafimow, D.; Marks, M. Editorial. Basic and Applied Social Psychology 2015, 37 (1), 1-2.

(10) Käll, L.; Storey, J. D.; MacCoss, M. J.; Noble, W. S. Assigning significance to peptides identified by tandem mass spectrometry using decoy databases. *J. Proteome Res.* **2008**, 7 (01), 29–34.

(11) Nesvizhskii, A. I. A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics. *J. Proteomics* **2010**, *73* (11), 2092–2123.

(12) The, M.; Tasnim, A.; Käll, L. How to talk about protein-level false discovery rates in shotgun proteomics. *Proteomics* **2016**, *16* (18), 2461–2469.

(13) Cohen, J. The Earth Is Round (p<. 05). Am. Psychol. 1995, 50 (12), 1103.

(14) Giai Gianetto, Q.; Combes, F.; Ramus, C.; Bruley, C.; Couté, Y.; Burger, T. Calibration plot for proteomics: A graphical tool to visually check the assumptions underlying FDR control in quantitative experiments. *Proteomics* **2016**, *16* (1), 29–32.

(15) Ramus, C.; Hovasse, A.; Marcellin, M.; Hesse, A. M.; Mouton-Barbosa, E.; Bouyssié, D.; Vaca, S.; Carapito, C.; Chaoui, K.; Bruley, C.; et al. Benchmarking quantitative label-free LC–MS data processing workflows using a complex spiked proteomic standard dataset. *J. Proteomics* **2016**, *132*, 51–62.

(16) As an aside, we mention that this difference between the theoretical and real histograms is well known and is classically referred to as a *p-value calibration issue*.¹⁸ It generally has multiple origins,

Tutorial

including: (1) small number of replicates (here 3 vs 3), which makes the test hardly robust; (2) dependences between the proteins tested, because protein abundances are not completely independent from one another; and (3) suboptimal preprocessing (for instance, peptide misidentifications), which introduce errors that are propagated in the data analysis pipeline. The CP4P package¹⁴ provides tools to visualize and limit the effects of incorrect calibration.

(17) Efron, B. Large-Scale Inference: Empirical Bayes Methods for Estimation, Testing, and Prediction; Cambridge University Press, 2012; Vol. 1.

(18) Hochberg, Y.; Benjamini, Y. More powerful procedures for multiple significance testing. *Statistics in medicine* **1990**, *9* (7), 811–818.

(19) Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., Ser. B 1995, 289–300.

(20) Benjamini, Y.; Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. *Ann. Statist.* **2001**, *29*, 1165–1188.

(21) Benjamini, Y.; Krieger, A. M.; Yekutieli, D. Adaptive linear stepup procedures that control the false discovery rate. *Biometrika* **2006**, 93 (3), 491–507.

(22) Tusher, V. G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. U. S. A.* **2001**, 98 (9), 5116–5121.

(23) Efron, B.; Tibshirani, R.; Storey, J. D.; Tusher, V. Empirical Bayes analysis of a microarray experiment. *J. Am. Stat. Assoc.* **2001**, *96* (456), 1151–1160.

(24) Storey, J. D. A direct approach to false discovery rates. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **2002**, 64 (3), 479–498.

(25) Storey, J. D.; Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl. Acad. Sci. U. S. A.* 2003, 100 (16), 9440-9445.

(26) Storey, J. D.; Taylor, J. E.; Siegmund, D. Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **2004**, 66 (1), 187–205.

(27) Keich, U.; Noble, W. S. On the importance of well-calibrated scores for identifying shotgun proteomics spectra. *J. Proteome Res.* **2015**, *14* (2), 1147–1160.

(28) To better understand the theoretical foundations of the concepts presented in this tutorial and to access the precise definitions of the various types of FDRs within the BH and ST families, any advanced reader will sooner or later study the corresponding literature, starting with the seminal 1995 paper of Benjamini and Hochberg,¹⁹ or even older articles, such as those referenced by Goeman and Solari.² At this point, the reader will find that the definitions used in this tutorial do not exactly match those in the earliest literature. The reasons for these apparent discrepancies are mainly historical: in fact, q-values and adjusted p-values, as interpretations of the FDR, appeared several years later. Thus to define the adjusted p-/q-values on top of FDR, one needs a trick: Basically, one first defines an intermediate notion, namely, the FDR level of each putative discovery (an individual property). Then, one defines adjusted p-/q-values/FDRs as a minimum over the FDR levels beyond the threshold. Let us note that confusion between FDR levels and FDR often leads to the wrong idea that an adjusted p-/q-value is not an FDR, as its looks like a minimum over several FDR values. However, it is not: Taking the minimum FDR level is equivalent to taking the minimum in eq 7, so that, in the end, the original and new definitions concur. To conclude this remark, let us sketch a brief intuition why taking the minimum is required: As explained in Section 4, is often tuned to overestimate the overall proportion of false discoveries in the entire data set. Taking the minimum thus helps avoid a too strong overestimation (and a too conservative FDR).

(29) Goeman, J. J.; Solari, A. Multiple hypothesis testing in genomics. *Statistics in medicine* **2014**, 33 (11), 1946–1978.

(30) Keller, A.; Nesvizhskii, A. I.; Kolker, E.; Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. *Anal. Chem.* **2002**, *74* (20), 5383–5392.

(31) Gupta, N.; Bandeira, N.; Keich, U.; Pevzner, P. A. Target-decoy approach and false discovery rate: when things may go wrong. *J. Am. Soc. Mass Spectrom.* **2011**, *22* (7), 1111–1120.

(32) Elias, J. E.; Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat. Methods* **2007**, *4* (3), 207–214.

(33) Levitsky, L. I.; Ivanov, M. V.; Lobas, A. A.; Gorshkov, M. V. (2016). Unbiased False Discovery Rate Estimation for Shotgun Proteomics Based on the Target-Decoy Approach. *J. Proteome Res.* **2017**, *16* (2), 393–397.

(34) Keich, U.; Kertesz-Farkas, A.; Noble, W. S. Improved false discovery rate estimation procedure for shotgun proteomics. *J. Proteome Res.* **2015**, *14* (8), 3148–3161.

(35) Käll, L.; Storey, J. D.; MacCoss, M. J.; Noble, W. S. Posterior error probabilities and false discovery rates: two sides of the same coin. *J. Proteome Res.* **2008**, *7* (1), 40–44.

(36) Käll, L.; Storey, J. D.; Noble, W. S. Non-parametric estimation of posterior error probabilities associated with peptides identified by tandem mass spectrometry. *Bioinformatics* **2008**, *24* (16), i42–i48.

(37) Käll, L.; Storey, J. D.; Noble, W. S. QVALITY: non-parametric estimation of q-values and posterior error probabilities. *Bioinformatics* **2009**, 25 (7), 964–966.

(38) Reiter, L.; Claassen, M.; Schrimpf, S. P.; Jovanovic, M.; Schmidt, A.; Buhmann, J. M.; Hengartner, M. O.; Aebersold, R. Protein identification false discovery rates for very large proteomics data sets generated by tandem mass spectrometry. *Mol. Cell. Proteomics* **2009**, *8* (11), 2405–2417.

(39) Pham, T. V.; Piersma, S. R.; Warmoes, M.; Jimenez, C. R. On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. *Bioinformatics* **2010**, *26* (3), 363–369.

(40) Lazar, C.; Gatto, L.; Ferro, M.; Bruley, C.; Burger, T. Accounting for the Multiple Natures of Missing Values in Label-Free Quantitative Proteomics Data Sets to Compare Imputation Strategies. J. Proteome Res. 2016, 15 (4), 1116–1125.

(41) Robin, X.; Turck, N.; Hainard, A.; Tiberti, N.; Lisacek, F.; Sanchez, J. C.; Müller, M. pROC: an open-source package for R and S + to analyze and compare ROC curves. *BMC Bioinf.* **2011**, *12* (1), 77.

(42) Käll, L.; Canterbury, J. D.; Weston, J.; Noble, W. S.; MacCoss, M. J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. *Nat. Methods* **2007**, *4* (11), 923–925.